Clinical Trial: Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Phase II Pilot Study of Hyper-CVAD Plus Rituximab for Previously Untreated Mantle Cell Lymphoma
Brief Summary: rituximab and modified (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
Detailed Summary: rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
Sponsor: University of Wisconsin, Madison
Current Primary Outcome: Complete Response Rate to Induction Therapy [ Time Frame: Median follow up of 37 months ]
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: University of Wisconsin, Madison
Dates:
Date Received: December 19, 2007
Date Started: June 2000
Date Completion:
Last Updated: June 25, 2014
Last Verified: June 2014